New Mood Among UK IVDs As Ambitious Pathology Modernization Scheme Gathers Pace
Executive Summary
NHS England's IVD and pathology sector is undergoing a major reorganization to make it fit for the future, responsive to growing demand and more patient-friendly. The plans are helping to change mindsets locally about how IVDs and pathology services should be delivered, according to speakers at a recent summit.
You may also be interested in...
IVDs Are Hitting An Adoption 'Glass Ceiling' While A £7Bn UK Opportunity Goes Begging
Diagnostics should be funded in a way that recognizes the value they bring. The UK IVD industry should also have a seat on the newly-formed Life Sciences Council. These are just two changes that would help diagnostics break through the adoption barrier in the UK and help the health-care system save "billions," say manufacturers.
Get Carter, But This Must Not Be A Missed Opportunity For NHS/Industry Partnerships
The UK medtech industry brands the Carter review and its NHS operating savings aims as “bold and ambitious”. Saving £5bn ($7.4bn) on non-pay NHS costs is the aim by 2020-21, and although that is less than a quarter of the projected funding shortfall that internal efficiency measures are being asked to address, the UK ABHI feels broadly positive about the initiative.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.